Sun Yat-sen University — Biomedical Watch V2

Traitements4programmes

Essais2liés

Publications8liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
ArtesunateThis is a multi-center, randomized, double-blind, placebo-controlled study. Study subjects are class III, IV, V, III+V, IV+V lupus nephritis patients, according to ISN/RPS 2003 classification of LN, with active lesion needing corticosteroid in combination with immunosuppressant therapy. Subjects who meet the eligibility criteria during screening will be randomized to 1 of 3 treatment groups in a 1:1:1 ratio: 25mg bid artesunate, 50mg bid artesunate or placebo plus standard of care (prednisone plus mycophenolate mofetil ［MMF］) for 6 month.	Lupus	Phase 4	À vérifier	China	À vérifier
Megestrol Acetate + Trastuzumab DeruxtecanThis study aims to evaluate whether the combination of Megestrol Acetate at the initiation of Trastuzumab Deruxtecan (T-DXd) treatment can effectively prevent and alleviate T-DXd-related fatigue, thereby improving the quality of life for advanced breast cancer patients.	Cancer	Phase 3	Traitement symptomatique	China	À vérifier
ArtesunateThis is a multi-center, randomized, double-blind, placebo-controlled study. Study subjects are class III, IV, V, III+V, IV+V lupus nephritis patients, according to ISN/RPS 2003 classification of LN, with active lesion needing corticosteroid in combination with immunosuppressant therapy. Subjects who meet the eligibility criteria during screening will be randomized to 1 of 3 treatment groups in a 1:1:1 ratio: 25mg bid artesunate, 50mg bid artesunate or placebo plus standard of care (prednisone plus mycophenolate mofetil ［MMF］) for 6 month.	Lupus	Phase 4	À vérifier	China	À vérifier
Megestrol Acetate + Trastuzumab DeruxtecanThis study aims to evaluate whether the combination of Megestrol Acetate at the initiation of Trastuzumab Deruxtecan (T-DXd) treatment can effectively prevent and alleviate T-DXd-related fatigue, thereby improving the quality of life for advanced breast cancer patients.	Cancer	Phase 3	Traitement symptomatique	China	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
Megestrol Acetate + Trastuzumab Deruxtecan	Cancer	Phase 3	NCT07543536	MEGA-TACT-BC3 — Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer	RECRUITING
Artesunate	Lupus	Phase 4	NCT03214731	AURORA — Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis	UNKNOWN

Publications

8

Molécule	Indication / population	Titre	Journal	Date
Artesunate		Artesunate ameliorates experimental autoimmune uveitis by inhibiting the LCN2-STAT3 axis and suppressing microglial activation.	Redox report : communications in free radical research
Artesunate		Artesunate-loaded bovine serum albumin nanoplatform with metal-polyphenol network coating for ferroptosis-driven breast cancer therapy.	International journal of pharmaceutics: X
Artesunate		Combinations of stem bark powders of Enantia chlorantha and Uvaria chamae showed antimalarial activities in mice.	Journal of ethnopharmacology
Artesunate		Correction: Zhao et al. Artesunate Inhibits Metastatic Potential in Cisplatin-Resistant Bladder Cancer Cells by Altering Integrins. 2025, , 570.	Cells
Artesunate		Integrated Bioinformatics Analysis Identifies FCER1G, IL1R2, and BST1 as Diagnostic Biomarkers and Therapeutic Targets in Sepsis.	Journal of clinical laboratory analysis
Artesunate		Drug repurposing as a promising therapeutic strategy against renal cell carcinoma.	Cancer chemotherapy and pharmacology
Artesunate		Two Cases of Malaria-Associated Acute Respiratory Distress Syndrome and Severe Pulmonary Complications From Plasmodium falciparum in Tanzania.	The American journal of case reports
Artesunate		In situ engineering of a self-healing drug-scaffold hydrogel to block platelet-driven postoperative metastasis.	Biomaterials